Seelos therapeutics announces year-end 2021 business and clinical update

New york, march 7, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year-end 2021 business and clinical update. "in the second half of 2021, we continued to accomplish several significant milestones and continued to execute in the face of one of the most difficult environments for publicly-traded biotech companies that i've seen in my career," said raj mehra ph.d.
SEEL Ratings Summary
SEEL Quant Ranking